BRPI0515334A - uso de um antìgeno de plasmodium - Google Patents

uso de um antìgeno de plasmodium

Info

Publication number
BRPI0515334A
BRPI0515334A BRPI0515334-4A BRPI0515334A BRPI0515334A BR PI0515334 A BRPI0515334 A BR PI0515334A BR PI0515334 A BRPI0515334 A BR PI0515334A BR PI0515334 A BRPI0515334 A BR PI0515334A
Authority
BR
Brazil
Prior art keywords
antigen
plasmodium antigen
relates
malaria
immunize against
Prior art date
Application number
BRPI0515334-4A
Other languages
English (en)
Inventor
Joseph D Cohen
Nadia Gabriela Tornieporth
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33306702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515334(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0515334A publication Critical patent/BRPI0515334A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

USO DE UM ANTìGENO DE PLASMODIUM A presente invenção refere-se a um novo uso de um antígeno da malária, para imunizar contra doença malárica. A invenção refere-se, em particular, ao uso de antígenos de esporozoíta, em particular proteína de circunsporozoíta (CS) ou seus fragmentos, para imunizar contra doença malárica severa.
BRPI0515334-4A 2004-09-16 2005-09-14 uso de um antìgeno de plasmodium BRPI0515334A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0420634A GB0420634D0 (en) 2004-09-16 2004-09-16 Vaccines
PCT/EP2005/009995 WO2006029887A2 (en) 2004-09-16 2005-09-14 Vaccines comprising plasmodium antigens

Publications (1)

Publication Number Publication Date
BRPI0515334A true BRPI0515334A (pt) 2008-07-22

Family

ID=33306702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515334-4A BRPI0515334A (pt) 2004-09-16 2005-09-14 uso de um antìgeno de plasmodium

Country Status (18)

Country Link
US (1) US20080102091A1 (pt)
EP (1) EP1791558A2 (pt)
JP (2) JP5670611B2 (pt)
KR (1) KR101362097B1 (pt)
CN (2) CN104027795A (pt)
AR (1) AR051023A1 (pt)
AU (1) AU2005284223B2 (pt)
BR (1) BRPI0515334A (pt)
CA (1) CA2579527C (pt)
GB (1) GB0420634D0 (pt)
IL (1) IL181733A0 (pt)
MA (1) MA28885B1 (pt)
MX (1) MX2007003160A (pt)
NO (1) NO20071523L (pt)
RU (1) RU2423994C2 (pt)
SG (2) SG159520A1 (pt)
TW (1) TW200621287A (pt)
WO (1) WO2006029887A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
BRPI0715581A2 (pt) 2006-07-18 2013-04-24 Glaxosmithkline Biolog Sa proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
LT2137210T (lt) * 2007-03-02 2016-12-27 Glaxosmithkline Biologicals Sa Naujas būdas ir kompozicijos
KR20100068390A (ko) 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2010108177A2 (en) * 2009-03-20 2010-09-23 University Of South Florida A method and composition using a dual specificity protein tyrosine phosphatase as an antimalarial drug target
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
TW201502136A (zh) 2013-03-15 2015-01-16 Glaxosmithkline Biolog Sa 疫苗
GB201416773D0 (en) * 2014-09-23 2014-11-05 Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford Novel Methods For Including An Imune Response
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
WO2017048689A1 (en) * 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010152A1 (en) * 1991-11-16 1993-05-27 Smithkline Beecham Biologicals S.A. HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG
SG49909A1 (en) * 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
US7060276B2 (en) * 2001-03-26 2006-06-13 The United States Of America As Represented By The Secretary Of The Army Plasmodium falciparum AMA-1 protein and uses thereof
WO2004044167A2 (en) * 2002-11-12 2004-05-27 Walter Reed Army Institute Of Research Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
WO2005017157A1 (en) * 2003-08-15 2005-02-24 Commonwealth Scientific And Industrial Research Organisation (Csiro) Methods and means for altering fiber characteristics in fiber-producing plants

Also Published As

Publication number Publication date
CA2579527C (en) 2016-06-21
RU2007109608A (ru) 2008-10-27
IL181733A0 (en) 2007-07-04
CN101056653A (zh) 2007-10-17
KR101362097B1 (ko) 2014-02-21
AR051023A1 (es) 2006-12-13
RU2423994C2 (ru) 2011-07-20
AU2005284223A1 (en) 2006-03-23
MX2007003160A (es) 2007-10-23
NO20071523L (no) 2007-03-28
EP1791558A2 (en) 2007-06-06
JP2012116849A (ja) 2012-06-21
AU2005284223B2 (en) 2011-12-15
JP5670611B2 (ja) 2015-02-18
SG159520A1 (en) 2010-03-30
CA2579527A1 (en) 2006-03-23
KR20070052342A (ko) 2007-05-21
TW200621287A (en) 2006-07-01
WO2006029887A2 (en) 2006-03-23
MA28885B1 (fr) 2007-09-03
SG193159A1 (en) 2013-09-30
CN104027795A (zh) 2014-09-10
WO2006029887A3 (en) 2006-05-11
JP2008513400A (ja) 2008-05-01
GB0420634D0 (en) 2004-10-20
US20080102091A1 (en) 2008-05-01
JP5632404B2 (ja) 2014-11-26

Similar Documents

Publication Publication Date Title
BRPI0515334A (pt) uso de um antìgeno de plasmodium
UA93508C2 (en) Anti-malaria vaccine
CR11307A (es) Vacunas
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
GB2434367A (en) Improved vaccines
ATE463515T1 (de) Chimaere rekombinante antigene von toxoplasma gondii
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
CR10555A (es) Vacunas para malaria
WO2005042581A8 (en) Modified anti-cd52 antibody
WO2007062819A3 (en) Multimeric complexes of antigens and an adjuvant
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
WO2009125231A3 (en) Anti-atheroma vaccine
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2006024240A3 (es) Composición vacunal contra el virus de la hepatitis c.
WO2007051004A3 (en) Conjugate vaccines for non-proteinaceous antigens
WO2007120603A3 (en) Immunogenic bcr-abl peptides and methods of use thereof
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
WO2005014654A3 (en) Product comprising a c4bp core protein and a monomeric antigen, and its use
AU2006264297A8 (en) Malaria MSP-1 C-terminal enhanced subunit vaccine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL